Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4Christopher Blackburn, Prakash Raman, Bing Guan et al.|Bioorganic & Medicinal Chemistry Letters|2006Cited by 73
Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive ControlNiresh Hariparsad, Donald Tweedie, Magalie Pardon et al.|Drug Metabolism and Disposition|2017Cited by 46
Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models.Jessica J. Huck, Karuppiah Kannan, Rachael Brake et al.|Journal of Clinical Oncology|2014Cited by 6
Considerations from the IQ induction working group in response to drug–drug interaction guidances from regulatory agenciesNiresh Hariparsad, Donald Tweedie, Heidi J. Einolf et al.|Drug Metabolism and Pharmacokinetics|2018Cited by 0